Global Patent Index - EP 1047691 A1

EP 1047691 A1 2000-11-02 - QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS

Title (en)

QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS

Title (de)

CHINOLINPIPERAZIN- UND CHINOLINPIPERIDIN DERIVATE, DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS KOMBINIERTE 5-HT1A, 5-HT1B UND 5-HT1D REZEPTOR ANTAGONISTEN

Title (fr)

DERIVES DE QUINOLEINEPIPERAZINE ET DE QUINOLEINEPIPERIDINE, LEUR PREPARATION ET LEUR UTILISATION EN TANT QU'ANTAGONISTES COMBINES DES RECEPTEURS 5-HT1A, 5-HT1B ET 5-HT1D

Publication

EP 1047691 A1 (EN)

Application

EP 98965729 A

Priority

  • EP 9807804 W
  • GB 9726364 A
  • GB 9726905 A
  • GB 9800317 A

Abstract (en)

[origin: WO9931086A1] The invention relates to compounds of formula (I) or a salt thereof in which R<a> is selected from a group of formula (i), (ii) or (iii); L is a group of formula -Y-C(=O)-DG- or -C(=O)-DG- or -DG-C(=O)- in which Y is -NH-, NR<5> where R<5> is C1-6alkyl, or Y is -CH2- or -O-; D is nitrogen, carbon or a CH group, or G is hydrogen or C1-6alkyl providing that D is nitrogen or a CH group, or G together with R<b1> forms a group W where W is (CR<16>R<17>)t where t is 2, 3 or 4 and R<16> and R<17> are independently hydrogen or C1-6alkyl or W is (CR<16>R<17>)u-J where u is 0, 1, 2 or 3 and J is oxygen, sulphur, CR<16>=CR<17>, CR<16>=N, =CR<16>O, =CR<16>S or =CR<16>-NR<17> provided that u is not 0 when J is oxygen or sulphur; X is nitrogen or carbon; R<b1>, R<b2> and R<b3> are independently hydrogen, halogen, hydroxy, C1-6alkyl, C2-6alkenyl, C3-6cycloalkyl, trifluoromethyl, C1-6alkoxy or aryl, or R<b1> together with G forms a group W as defined above; R<c> is hydrogen or C1-6alkyl; and <o>-------</o> is a single bond when X is nitrogen or a single or double bond when X is carbon; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.

IPC 1-7 (main, further and additional classification)

C07D 401/12; A61K 31/47; A61K 31/505; C07D 215/42; C07D 215/46; C07D 413/12; C07D 471/04

IPC 8 full level (invention and additional information)

C07D 215/42 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61P 25/00 (2006.01); A61P 25/24 (2006.01); A61P 43/00 (2006.01); C07D 215/46 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 471/04 (2006.01)

CPC (invention and additional information)

C07D 401/12 (2013.01); C07D 215/46 (2013.01); C07D 413/12 (2013.01); C07D 471/04 (2013.01)

Citation (search report)

See references of WO 9931086A1

Designated contracting state (EPC)

BE CH DE ES FR GB IT LI NL

EPO simple patent family

WO 9931086 A1 19990624; CA 2313125 A1 19990624; EP 1047691 A1 20001102; JP 2002508366 A 20020319

INPADOC legal status


2002-07-24 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20020116

2001-08-22 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20010705

2000-11-02 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20000523

2000-11-02 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): BE CH DE ES FR GB IT LI NL